# LUMINOSITY

Source: https://onco.cc/trials/luminosity/  
OnCo record `luminosity` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The single-arm study behind the first c-Met-directed antibody-drug conjugate approval in lung cancer: tumours shrank in about a third of patients whose cancers carried high c-Met protein, with eye and nerve side effects to watch.

## Summary

LUMINOSITY, trial NCT03539536 sponsored by AbbVie and published in the Journal of Clinical Oncology in 2024, gave telisotuzumab vedotin to previously treated patients with non-squamous, EGFR wild-type non-small-cell lung cancer whose tumours overexpressed c-Met protein on immunohistochemistry. The objective response rate was 28.6% overall, 34.6% in the c-Met high group and 22.9% in the intermediate group, with peripheral sensory neuropathy, peripheral oedema and keratitis among the notable side effects. The c-Met high results supported the 2025 US accelerated approval of Emrelis, the first c-Met-directed ADC in lung cancer; the confirmatory phase 3 trial TeliMET NSCLC-01 is ongoing.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-04
- Registry id: NCT03539536
- Phase: 2
- Setting: Previously treated c-Met protein-overexpressing, EGFR wild-type non-squamous NSCLC: telisotuzumab vedotin single arm
- Sponsor: AbbVie
- Enrolled: 270
- Result: ORR 28.6% overall; 34.6% in c-Met high, 22.9% in c-Met intermediate.
- Outcomes: Objective response rate (independent review): Telisotuzumab vedotin, c-Met high 34.6% vs Telisotuzumab vedotin, c-Met intermediate 22.9%

## Sources

- ClinicalTrials.gov NCT03539536: https://clinicaltrials.gov/study/NCT03539536
- Camidge et al., Telisotuzumab vedotin monotherapy in previously treated c-Met protein-overexpressing non-squamous NSCLC: LUMINOSITY (Journal of Clinical Oncology 2024): https://doi.org/10.1200/JCO.24.00720

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [MET exon 14 and MET-amplified non-small-cell lung cancer](https://onco.cc/cancers/met-altered-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [MET](https://onco.cc/targets/met/)
- drugs: [Telisotuzumab vedotin](https://onco.cc/drugs/telisotuzumab-vedotin/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)
- key papers: [Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial](https://onco.cc/key-papers/paper-luminosity-jto-clin-res-rep-2026-update/), [Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR -Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial](https://onco.cc/key-papers/paper-luminosity-j-clin-oncol-2024/)

---
JSON: https://onco.cc/api/v1/entities/luminosity.json